Board of Directors

Mr. Pilnik recently retired as Executive Vice President and President of Quintiles Commercial Solutions, a global pioneer in pharmaceutical services.

Mr. Pilnik has a 30-year career in healthcare at Eli Lilly and Company and Quintiles Transnational.  Most recently at Quintiles, Mr. Pilnik was the Executive Vice President and President for the Global Commercial Solutions, an outsourcing business to over 70 pharma and biotech companies.  Prior to that, he spent 25 years at Eli Lilly and Company where he held several leadership positions. As Group Vice President and Chief Marketing Officer at the company, he was directly responsible for commercial strategy, market research, new product planning and the medical marketing interaction. As President of Eli Lilly Europe, Middle East and Africa and the Commonwealth of Independent States (CIS), a regional organization of former Soviet Republics, he oversaw 50 countries and positioned Eli Lilly as the fastest growing pharmaceutical company in the region. During his tenure at Eli Lilly, Mr. Pilnik also held several marketing and sales management positions in the United States, Europe and Latin America.

Mr. Pilnik  sits on the board of directors of Certara, a private biotech company focused on drug development modeling and biosimulation; Chiltern, a private leading mid-tier Clinical Research Organization; and the Fuqua School of Business at Duke University.  He holds a Bachelor of Arts in Economics from Duke University and an MBA from the Kellogg School of Management at Northwestern University.

As a Clinical Professor of Cardiac Sciences and Pediatrics at the University of Calgary, Dr. Giuffre maintains a portfolio of clinical practice, physician leadership and biotechnology consultation.

He is actively involved in both pediatric cardiology, health care administration, and the biotechnology business sector.  As a biotechnology consultant, Dr. Giuffre has been involved with RedSky Inc. (acquired by Research in Motion), MDMI, and MedMira Inc.  He is currently on the board of directors of FoodChek Inc, and SCS Inc.  In addition, Dr. Giuffre is a board member of the Canadian Medical Association and a past board member of Unicef Canada and the Alberta Medical Association.  Dr. Giuffre has received a Certified and Registered Appointment and a Distinguished Fellow appointment by the American Academy of Cardiology.  In 2005, he was awarded Physician of the Year by the Calgary Medical Society.

Dr. Giuffre is former President of the Calgary and Area Physicians Association (CAPA) and a past representative to the board of the Calgary Health Region.  Dr Giuffre holds a Bachelor of Science in cellular and microbial biology, an MD and an MBA. His Canadian Royal College board certified specialties include Pediatrics and Pediatric Cardiology with a subspecialty in Pediatric Electrophysiology. His is a consultant for the Palix Foundation.

Mr. Parsons served as Vice President of Finance for DiaMedica from October 2010 until May 2014. Mr. Parsons currently serves as the Chief Financial Officer and Corporate Secretary of Trillium Therapeutics Inc., a NASDAQ-listed immune-oncology company since August 2011. He is also a director and audit committee chair of Sernova Corp (TSXV). He has been a CFO in the life sciences industry since 2000 with experience in therapeutics, diagnostics and devices. Mr. Parsons has a Master of Accounting degree from the University of Waterloo and is a Chartered Professional Accountant and Chartered Accountant.

Mr. Pauls has served as President, Chief Executive Officer, and director since 2010 and was Chairman of the board from 2008 to 2014. Mr. Pauls was previously the co-founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund. Prior to CentreStone, he was with Centara Corporation, another early stage venture capital fund. Before this, Mr. Pauls specialized in asset-backed securitization and structured finance at the General Motors Acceptance Corporation in Minnesota.  He received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.

Dr. Xiao is the Managing Director of Hermed Capital, a healthcare investment fund in partnership with Shanghai Fosun Pharmaceutical Group and SK Group. Prior to Hermed Capital, he was the Associate General Manager of Shanghai Fosun Pharmaceutical Group where he was the deputy chief of the IPO team for the Fosun Pharma Listing in Hong Kong Exchange and the deputy director of Fosun Pharmaceutical Technological Center in charge of evaluating new technology and R&D and investment. 

Dr. Xiao has a PhD in Pharmacology and conducted his postdoctoral research at University of Rochester (NY), co-founding a pharmaceutical company with Dr. Paul Okunieff and winning Small Business Technology Transfer support, a U.S. Small Business Administration program to facilitate joint venture opportunities between small businesses and nonprofit research institutions. He is a member of Bio China Advisor Committee.